Establishment of the cisplatin-resistant (CR) human ovarian cancer lines OVCAR8CR and SKOV3CR

Exponentially growing human ovarian cancer cell lines OVCAR8 and SKOV3 were treated with 0.5 μM cisplatin (dissolved in dimethylformamide or DMF; the cisplatin stock solution was aliquoted and kept at –80°C) for 72 h. Viable cells were replated and grown up, followed by one more round treatment of 0.5 μM cisplatin. Similar selection scheme was carried out by escalating cisplatin concentrations gradually to 1.0 μM, 1.5 μM, 2.0 μM, 3.0 μM and 5.0 μM, yielding the stable and robust cisplatin-resistant cell lines that are designated as OVCAR8CR and SKOV3CR. These lines were further characterized in the reported work.